Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma

Molecular Oncology

Volumn 10, Issue 4, 2016, Pages 625-634

  Crommentuijn, Matheus H W ^a,b,c   Maguire, Casey A ^a,b   Niers, Johanna M ^a,b,c   Vandertop, W Peter ^c   Badr, Christian E ^a,b   Würdinger, Thomas ^b,c   Tannous, Bakhos A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c University of Amsterdam   (Netherlands)

Author keywords

Adeno associated virus; Cardiac glycoside; Gene therapy; Glioblastoma; Lanatoside C; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CARDIAC GLYCOSIDE; FIREFLY LUCIFERASE; LANATOSIDE C; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; LANATOSIDE; LANATOSIDE A; TNFSF10 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACRANIAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; DEPENDOPARVOVIRUS; DRUG SCREENING; GENE VECTOR; GENETICS; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DEPENDOVIRUS; GENETIC VECTORS; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; LANATOSIDES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84950115333     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.11.011     Document Type: Article

References (31)

1. Badr C.E., Wurdinger T., Nilsson J., Niers J.M., Whalen M., Degterev A., Tannous B.A. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro-oncology 2011, 13:1213-1224.
2. Bouralexis S., Findlay D.M., Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005, 10:35-51.
3. Bowers W.J., Breakefield X.O., Sena-Esteves M. Genetic therapy for the nervous system. Hum. Mol. Genet. 2011, 20:R28-R41.
4. Broekman M.L., Comer L.A., Hyman B.T., Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006, 138:501-510.
5. Cearley C.N., Vandenberghe L.H., Parente M.K., Carnish E.R., Wilson J.M., Wolfe J.H. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 2008, 16:1710-1718.
6. Ding L., Yuan C., Wei F., Wang G., Zhang J., Bellail A.C., Zhang Z., Olson J.J., Hao C. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 2011, 29:511-520.
7. Duiker E.W., Dijkers E.C., Lambers Heerspink H., de Jong S., van der Zee A.G., Jager P.L., Kosterink J.G., de Hooge Vries E.G., Lub-de M.N. Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. Br. J. Pharmacol. 2012, 165:2203-2212.
8. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
9. Gray S.J., Matagne V., Bachaboina L., Yadav S., Ojeda S.R., Samulski R.J. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 2011, 19:1058-1069.
10. Hao C., Beguinot F., Condorelli G., Trencia A., Van Meir E.G., Yong V.W., Parney I.F., Roa W.H., Petruk K.C. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 2001, 61:1162-1170.
11. Ibrahim S.M., Ringel J., Schmidt C., Ringel B., Müller P., Koczan D., Thiesen H.J., Löhr M. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001, 23:72-79.
12. Jane E.P., Premkumar D.R., Pollack I.F. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-(kappa)B signaling pathway. Mol. Cancer Ther. 2011, 10:198-208.
13. Johansson S., Lindholm P., Gullbo J., Larsson R., Bohlin L., Claeson P. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs 2001, 12:475-483.
14. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., Logsdon C.D., Abbruzzese J.L., McConkey D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:2251-2260.
15. Ma H.-I.I., Hueng D.-Y.Y., Shui H.-A.A., Han J.-M.M., Wang C.-H.H., Lai Y.-H.H., Cheng S.-Y.Y., Xiao X., Chen M.-T.T., Yang Y.-P.P. Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation. Int. J. Mol. Sci. 2014, 15:4393-4414.
16. Maguire C.A., Bovenberg M.S., Crommentuijn M.H.W., Niers J.M., Kerami M., Teng J., Sena-Esteves M., Badr C.E., Tannous B.A. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol. Ther. Nucleic Acids 2013, 2:e99.
17. Maguire C.A., Crommentuijn M.H.W., Mu D., Hudry E., Serrano-Pozo A., Hyman B.T., Tannous B.A. Mouse gender influences brain transduction by intravascularly administered AAV9. Mol. Ther. 2013, 21:1470-1471.
18. Maguire C.A., Meijer D.H., LeRoy S.G., Tierney L.A., Broekman M.L., Costa F.F., Breakefield X.O., Stemmer-Rachamimov A., Sena-Esteves M. Preventing growth of brain tumors by creating a zone of resistance. Mol. Ther. 2008, 16:1695-1702.
19. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818. (New York, N.Y.).
20. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
21. Panner A., James C.D., Berger M.S., Pieper R.O. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell. Biol. 2005, 25:8809-8823.
22. Seol D.-W.W. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem. Biophys. Res. Commun. 2011, 416:222-225.
23. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
24. Song J.H., Song D.K., Pyrzynska B., Petruk K.C., Van Meir E.G., Hao C. TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol. 2003, 13:539-553.
25. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
26. Wakimoto H., Kesari S., Farrell C.J., Curry W.T., Zaupa C., Aghi M., Kuroda T., Stemmer-Rachamimov A., Shah K., Liu T.-C.C., Jeyaretna D.S., Debasitis J., Pruszak J., Martuza R.L., Rabkin S.D. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009, 69:3472-3481.
27. Wang J.K., Portbury S., Thomas M.B., Barney S., Ricca D.J., Morris D.L., Warner D.S., Lo D.C. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl. Acad. Sci. U.S.A 2006, 103:10461-10466.
28. de Wilt L.H., Kroon J., Jansen G., de Jong S., Peters G.J., Kruyt F.A. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?. Crit. Rev. Oncol. Hematol. 2013, 85:363-372.
29. Wu X., He Y., Falo L.D., Hui K.M., Huang L. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Mol. Ther. 2001, 3:368-374.
30. Xiang H., Nguyen C.B., Kelley S.K., Dybdal N., Escandón E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab. Dispos 2004, 32:1230-1238.
31. Zhang H., Yang B., Mu X., Ahmed S.S., Su Q., He R., Wang H., Mueller C., Sena-Esteves M., Brown R., Xu Z., Gao G. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 2011, 19:1440-1448.